Document Detail


Promising therapeutic targets for antileishmanial drugs.
MedLine Citation:
PMID:  12223057     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Current treatments for the parasitic disease leishmaniasis are unsatisfactory due to their route of administration, toxicity and expense. Resistance is also developing to first-line antimonial drugs. Fortunately, a handful of antileishmanial agents, such as the orally available compound miltefosine, are currently in clinical trials. In addition, several promising drug targets and lead molecules are being studied with the goal of developing new antileishmanial agents. Drug candidates have been identified through the continued investigation of parasite sterol metabolism and parasite proteases. New antileishmanial molecules have also been discovered through the study of novel targets and pathways, such as the bisphosphonate inhibitors of isoprenoid biosynthesis. This review presents a synopsis of the drug targets and lead compounds that have been investigated over the last few years against leishmaniasis, gives a perspective on the chemotherapeutic potential of each and discusses some of the obstacles to antileishmanial drug development.
Authors:
Karl A Werbovetz
Related Documents :
21235757 - Use of the atmospheric generators for capnophilic bacteria genbag-co2 for the evaluatio...
19549927 - Extracellular matrix molecules: potential targets in pharmacotherapy.
18755517 - Yeast chemical genomics and drug discovery: an update.
19853457 - Actinobacteria as mutualists: general healthcare for insects?
18809437 - Repeated intravenous amphetamine exposure: rapid and persistent sensitization of 50-khz...
1807747 - Smart pharmacy cards to automate patient records for prospective drug utilization review.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on therapeutic targets     Volume:  6     ISSN:  1744-7631     ISO Abbreviation:  Expert Opin. Ther. Targets     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-09-11     Completed Date:  2006-04-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  101127833     Medline TA:  Expert Opin Ther Targets     Country:  England    
Other Details:
Languages:  eng     Pagination:  407-22     Citation Subset:  IM    
Affiliation:
Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA. werbovetz.1@osu.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antiprotozoal Agents / pharmacology*,  therapeutic use
Chalcones / metabolism
Clinical Trials as Topic
Drug Design*
Drug Evaluation, Preclinical
Folic Acid Antagonists / metabolism
Humans
Leishmania / drug effects*,  metabolism
Leishmaniasis / drug therapy*,  parasitology
Lipid Metabolism / drug effects
Pentamidine / metabolism
Polyamines / metabolism
Protozoan Proteins / antagonists & inhibitors,  drug effects
Tubulin / drug effects
Chemical
Reg. No./Substance:
0/Antiprotozoal Agents; 0/Chalcones; 0/Folic Acid Antagonists; 0/Polyamines; 0/Protozoan Proteins; 0/Tubulin; 100-33-4/Pentamidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variagenics, inc.
Next Document:  The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block ...